New inhibitor has potential as cancer drug

Laboratory experiments have previously shown that cancer cells overproduce an enzyme, heparanase, which splits the body’s own polysaccharide heparan sulfate into shorter fragments. The amount of enzyme is related to the degree of malignancy. Today a study is being published in the journal Nature Chemical Biology in which Uppsala University researchers show, on the basis of animal models, that an inhibitor for heparanase would be extremely interesting as a drug candidate.

Heparan sulfate is a polysaccharide, that is, a chain of linked sugar units, with sulfate groups in different positions. These chains are found on the surface of practically every cell in the body. The sulfate groups enable binding to a number of proteins, such as inflammation proteins and growth factors. Heparan sulfate can thereby regulate different processes in the body, during embryonic development, for example, but also in various conditions of sickness. The capacity for protein-binding generally increases the more sulfate groups there are on the polysaccharide.

The enzyme heparanase splits heparan sulfate at certain points and converts the long chains into shorter fragments. Research at other laboratories has shown that cancer cells in many cases overproduce heparanase and that the amount of heparanase correlates with the degree of malignancy of the cancer cells and their capacity to metasthesize. The connection is believed to have multiple explanations. Heparanase helps cancer cells make their way through tissue barriers, but it also stimulates the heightened generation of blood vessels that is necessary for tumor growth. The fragments function as carriers of growth factors that can promote tumor growth in many ways.

In the current project the scientists introduced the gene for human heparanase into a mouse, so that the enzyme would be overproduced in several organs. Besides the expected splitting of heparan sulfate, they found that the metabolism of the polysaccharide was stimulated, but that the number of sulfate groups increased at the same time. The ‘high-sulfated’ fragments released by the enzyme evince dramatically increased binding to certain growth factors of potential importance to tumor growth.

When they examined heparan sulfate from authentic cancer cells instead, or from cancer tissue that had overproduced heparanase, it was found that here too there was an increase in the number of sulfate groups compared with heparan sulfate from corresponding normal cells/tissues. The findings indicate that producing an inhibitor for heparanase is an urgent step in discovering new drugs for cancer.

Source: Uppsala University

Related stories:

Moisturisers cause skin cancer in mice: study
Moisturisers used by millions of people induced skin cancer in experiments on mice, a study released Thursday said, as experts expressed strong doubts over any possible risk to humans from creams.
Study shows zinc doesn't help head and neck cancer patients
Zinc sulfate, a supplement thought to be helpful in regaining the sense of taste for some head and neck cancer patients after radiation therapy, has been found to have no significant impact on preventing or curing taste alteration, according to a study released today in the International Journal for Radiation Oncology*Biology*Physics, the official journal of ASTRO.
A sweet step toward new cancer therapies
By recognizing sugars, a technique developed by University of Michigan analytical chemist Kristina Hakansson sets the stage for new cancer diagnosis and treatment options.
Suspicion lingers over bisphenol A and breast cancer
Bisphenol A, a common industrial chemical claimed to speed the growth of human breast and ovarian cancers, retains its carcinogenic properties even after being modified by body processes, report Indiana University and University of California at Berkeley scientists in the Aug. 28th issue of Chemistry & Biology, a Cell Press journal.
Common treatment to delay labor decreases preterm infants' risk for cerebral palsy
Intravenous magnesium sulfate supplementation before preterm delivery cuts the risk for handicapping cerebral palsy in half, according to research led by University of Alabama at Birmingham (UAB) obstetrician Dwight Rouse, M.D., and published in the Aug. 28 issue of The New England Journal of Medicine.
Dirty smoke from ships found to degrade air quality in coastal cities
Ah, nothing like breathing clean coastal air, right? Think again. Chemists at UC San Diego have measured for the first time the impact that dirty smoke from ships cruising at sea and generating electricity in port can have on the air quality of coastal cities.
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Studying volcanoes with balloons
People do all kinds of crazy things in Hawaii, but flying balloons over a volcano usually isn't one of them. Unless you're Adam Durant, that is.

News discussion:

Medicine & Health news